Compare ETHZ & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETHZ | MREO |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United Kingdom |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 67.5M |
| IPO Year | N/A | 2017 |
| Metric | ETHZ | MREO |
|---|---|---|
| Price | $3.54 | $0.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 591.9K | ★ 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $0.20 |
| 52 Week High | $24.44 | $2.94 |
| Indicator | ETHZ | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 32.66 |
| Support Level | $2.99 | $0.35 |
| Resistance Level | $5.63 | $0.45 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 59.57 | 10.45 |
ETHZilla Corporation is a technology company in the decentralized finance industry. It seeks to connect financial institutions, businesses and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It generates recurring revenues through various DeFi protocols that improve Ethereum network integrity and security. The group enables the seamless tokenization of traditional assets by bringing them on-chain. Leveraging its proprietary protocol solutions, ETHZilla supports DeFi transactions, asset digitization across various Layer 2 Ethereum networks. The platform is focused on delivering tokenization services, DeFi protocol integrations, blockchain analytics, gateways for converting traditional assets to digital forms.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).